Innovation Pharmaceuticals Phase 2b Psoriasis Study On-Track for Completion in December 2017; Company a Sponsor at Upcoming Symposium on Hidradenitis Suppurativa

BEVERLY, Mass., October 31, 2017 (GLOBE NEWSWIRE) – Innovation Pharmaceuticals Inc. (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report continued developments in its dermatology franchise.

The Company’s randomized, placebo-controlled Phase 2b clinical trial of Prurisol for chronic, moderate-to-severe plaque psoriasis (see NCT02949388), enrolling a total of 199 patients, remains on-track for completion in December. Separately, building upon promising results seen to date demonstrating its anti-inflammatory, anti-infective and immunomodulatory properties, the Company is looking to expand Brilacidin into treating multiple serious chronic skin diseases. The Company plans to participate in upcoming dermatology conferences, including as a sponsor in this week’s Symposium on Hidradenitis Suppurativa Advances to be held November 4-5, 2017, in Detroit, MI.

Brilacidin’s potential application in dermatology to provide improved treatment options for people in need is discussed below. 

From a scientific perspective, defensins—which Brilacidin was designed to mimic—play an important and multifunctional role in regulating the skin micro-environment. The increased susceptibility of people with Atopic Dermatitis (Eczema) to S. aureus infections, significantly complicating this skin condition and against which Brilacidin has been shown to have potent efficacy, is thought to be influenced by the impaired expression of Host Defense Proteins (HDPs). Up to a combined 50 million people, in the U.S. and major European markets, are affected by Eczema. Brilacidin also exhibits strong anti-inflammatory effects on key effector cells involved in the etiology of Hidradenitis Suppurativa (HS), a burdensome skin disease affecting 1 to 4 percent of the world’s population, and for which there currently is only one approved marketed treatment (Humira). Brilacidin’s antimicrobial and wound healing properties might similarly benefit HS sufferers. Pre-clinical lab work also indicates impressive Minimum Inhibitory Concentration (MIC) values when Brilacidin was tested against Propionibacterium spp.—a type of bacteria expressed in Acne—compared to other antibiotics, such as Erythromycin, Clindamycin, Minocycline, Doxycycline and Metronidazole.

One key aspect of Brilacidin’s Mechanism of Action, inhibiting Phosphodiesterase 4 (PDE4), might also contribute to its therapeutic potential in treating skin diseases.

Linked below is additional information, published on the Company’s website, elaborating on Brilacidin’s treatment potential in various dermatological conditions.

·         “Brilacidin’s Potential Application in Dermatology”
http://www.ipharminc.com/new-blog/2017/6/5/brilacidins-potential-application-in-dermatology

·         “The Clinical Need and Market Opportunity in Atopic Dermatitis”
http://www.ipharminc.com/new-blog/2017/6/21/the-market-opportunity-in-atopic-dermatitis

·         “Toward Developing Newer Treatments for Hidradenitis Suppurativa”
http://www.ipharminc.com/new-blog/2017/5/30/hidradenitis-suppurativa-acne-inversa